Alobresib

DB14970InvestigationalSmall molecule

Alobresib is under investigation in clinical trial NCT02607228 (Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate...

Formula / weight: C₂₆H₂₃N₅O₂ · 437.503 g/mol (avg)
Code names: GS-5829

Resolves to

Compound

UNII3QBL0BLP3DCAS1637771-14-2ChEMBLCHEMBL3982690

Structure

InChIKeyCMSUJGUHYXQSOK-UHFFFAOYSA-NSMILESCC1=C(C(C)=NO1)C1=CC(=C2N=C(NC2=C1)C1CC1)C(O)(C1=CC=CC=N1)C1=NC=CC=C1

What you can answer from here — as of April 23, 2025

3Clinical trialsPhase, status and sponsor resolved per trial

Which companies are running trials of Alobresib, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account